CALL/ROCHE GS/340/0.1/21.06.24 Stock

Warrant

DE000GK74KK4

Real-time BOERSE MUENCHEN 10:27:18 2024-06-11 am EDT
0.001 EUR 0.00% Intraday chart for CALL/ROCHE GS/340/0.1/21.06.24
3 months-96.97%
6 months-98.44%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-11 0.001 0.00%
24-06-10 0.001 0.00%
24-06-07 0.001 0.00%
24-06-06 0.001 0.00%
24-06-05 0.001 0.00%

Real-time BOERSE MUENCHEN

Last update June 11, 2024 at 10:27 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GK74KK
ISINDE000GK74KK4
Date issued 2022-07-06
Strike 340 CHF
Maturity 2024-06-21 (10 Days)
Parity 10 : 1
Emission price 2.1
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.41
Lowest since issue 0.001
Spread 0.199
Spread %99.50%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
239.7 CHF
Average target price
277.5 CHF
Spread / Average Target
+15.78%
Consensus